AU1265295A - Reducing likelihood of vascular disorders in susceptible patients - Google Patents

Reducing likelihood of vascular disorders in susceptible patients

Info

Publication number
AU1265295A
AU1265295A AU12652/95A AU1265295A AU1265295A AU 1265295 A AU1265295 A AU 1265295A AU 12652/95 A AU12652/95 A AU 12652/95A AU 1265295 A AU1265295 A AU 1265295A AU 1265295 A AU1265295 A AU 1265295A
Authority
AU
Australia
Prior art keywords
vascular disorders
susceptible patients
reducing likelihood
likelihood
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12652/95A
Inventor
Sami A. Hashim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAMI A HASHIM
Original Assignee
SAMI A HASHIM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAMI A HASHIM filed Critical SAMI A HASHIM
Publication of AU1265295A publication Critical patent/AU1265295A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
AU12652/95A 1993-12-10 1994-12-05 Reducing likelihood of vascular disorders in susceptible patients Abandoned AU1265295A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16527293A 1993-12-10 1993-12-10
US165272 1993-12-10
PCT/US1994/013899 WO1995015750A1 (en) 1993-12-10 1994-12-05 Reducing likelihood of vascular disorders in susceptible patients

Publications (1)

Publication Number Publication Date
AU1265295A true AU1265295A (en) 1995-06-27

Family

ID=22598205

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12652/95A Abandoned AU1265295A (en) 1993-12-10 1994-12-05 Reducing likelihood of vascular disorders in susceptible patients

Country Status (2)

Country Link
AU (1) AU1265295A (en)
WO (1) WO1995015750A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932624A (en) * 1995-10-17 1999-08-03 Herbert; Victor D. Vitamin supplement composition
US6265391B1 (en) 1995-10-17 2001-07-24 Upsher-Smith Laboratories, Inc. Method for preventing peripheral nerve damage
US6129918A (en) * 1998-08-13 2000-10-10 Wakunaga Of America Co., Ltd. Method and pharmaceutical composition for reducing serum homocysteine concentration
EP1105739A1 (en) 1998-08-20 2001-06-13 Axis-Shield Asa Assay method for cardiovascular disease
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
BE1012495A3 (en) * 1999-03-02 2000-11-07 Messadek Jallal Glycine betaine-for its use antithrombotic.
US7226916B1 (en) * 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
BE1015608A6 (en) 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
WO2006113978A2 (en) 2005-04-27 2006-11-02 Jallal Messadek Insulins combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931818A (en) * 1957-04-29 1960-04-05 Cutter Lab Process of treating lecithin for freeing it of its depressor factor
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
US4902718A (en) * 1988-04-08 1990-02-20 Bayless Robert K Calcium homeostasis compositions and methods for controlling calcium metabolism
EP0347864A3 (en) * 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Anti-atherogenic agents

Also Published As

Publication number Publication date
WO1995015750A1 (en) 1995-06-15

Similar Documents

Publication Publication Date Title
AU8545691A (en) Low profile catheter and guidewire
AU2253492A (en) Vascular occlusion removal devices and methods
AU671484B2 (en) Suction catheter assemblies and valves
AU7621794A (en) Vascular prostheses
AU7381094A (en) Triple lumen catheter
AU7867994A (en) Hemofiltration of mediator-related diseases
AU6316794A (en) Medical stent
AU8264091A (en) Balloon catheter kit and method
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
AU6391394A (en) Medical devices and methods of manufacture
AU2381895A (en) Treatment of warts using anthralins and occlusion
AU2084092A (en) Spongy material consisting essentially of hyaluronic acid or its derivatives, and its use in microsurgery
AU1173195A (en) Treatment of immunoregulatory disorders
AU3625295A (en) Low profile defibrillation catheter
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
AU1265295A (en) Reducing likelihood of vascular disorders in susceptible patients
AU7254894A (en) Activated human factor viii and method of preparation
AU7065694A (en) Catheter and method of use thereof
AU7384094A (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
AU4787593A (en) Heterocyclic derivatives useful in the treatment of cardiovascular diseases
AU1800195A (en) Durable patient chair
AU4569993A (en) Bile acid derivative and use thereof in therapy
AU7602894A (en) Use of 2-deoxycoformycin (pentostatin) for treating cerebral and cardiovascular disorders
AU1401495A (en) Human vascular ibp-like growth factor
AU7011098A (en) Treatment of adverse effects associated with administration of extracellular hemoglobin